Drug delays type 1 diabetes in people at high risk: Study

Drug delays type 1 diabetes in people at high risk: Study

In a first, scientists have developed a treatment that can delay type 1 diabetes by two or more years among people who are at high risk.

Also Read | Diabetes and the month of fasting

The research, published in the New England Journal of Medicine, involved treatment with an anti-CD3 monoclonal antibody (teplizumab).

Researchers from Yale University in the US enrolled 76 participants ages 8-49 who were relatives of people with type 1 diabetes, had at least two types of diabetes-related autoantibodies (proteins made by the immune system), and abnormal glucose (sugar) tolerance.

Also Read | Diabetes and Ramadhan

Type 1 diabetes develops when the immune system’s T cells mistakenly destroy the body’s own insulin-producing beta cells. Insulin is needed to convert glucose into energy. Teplizumab targets T cells to lessen the destruction of beta cells.

“Previous clinical research found that teplizumab effectively slows the loss of beta cells in people with recent onset clinical type 1 diabetes, but the drug had never been tested in people who did not have clinical disease,” said Kevan C Herold, of Yale University.

Also Read | Indian women at high death risk from diabetes: Study

Faster progression of type 1 diabetes is associated with a highly active immune system, which may explain the impact of immune system-modulating drugs like teplizumab. The research team also cautioned that the study had limitations, including the small number of participants, their lack of ethnic diversity, and that all participants were relatives of people with type 1 diabetes, potentially limiting the ability to translate the study broadly.


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *